Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Indiana University
How would you approach a patient with grade 1/2 pancreatic neuroendocrine tumor after progressing on octreotide?
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
Answer from: Medical Oncologist at Community Practice
Tem/cape -- responses are good for pancreatic NET. PRRT Is great but so expensive. I’m finding it so hard to get.
Sign in or Register to read more
6227
Related Questions
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
Do you consider ablative radiation therapy for oligometastatic colon cancer with 5 pulmonary lesions responding to chemotherapy?
What is your approach to determining fitness for patients to undergo CAR-T therapy for relapsed/refractory multiple myeloma, and any absolute perceived contraindications for CAR-T?
What is the best treatment approach to a patient with HGBCL w/ FISH translocation of BCL-6 and c-Myc given new classification of this entity?
Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?
In a patient with amyloidosis and abnormal liver function but child Pugh A, would you still proceed with SABR for a liver metastasis?
What treatment sequence do you follow for patients with rectal cancer who are candidates for both PROSPECT and TNT/Watch and wait?
What second-line therapy would you offer a patient with metastatic colon cancer with HER2 IHC 3+ amplification and KRAS G12D mutation whose disease progressed on FOLFOX?
Would you offer inguinal nodal RT to a patient with anal SCC (pT1N1a, + inguinal node) following APR in the setting of prior prostate + pelvic nodal radiation?